Alexion has said it can ramp up production if the drug works in trials but what it has not mentioned is its cost: Ultomiris is hugely expensive when used in rare diseases, costing several thousand ...

Alexion wants to buy Swedish rare diseases biotech Wilson Therapeutics for around $855 million, which is developing a late-stage drug to treat the inherited condition Wilson Disease. In a statemen ...

The company has decided to switch gears following disappointing data for a monoclonal antibody targeting a rare maternal ...

Full efficacy and safety data will be analyzed at 52 weeks. Alexion, the rare disease group at AstraZeneca, plans to share the data with global health authorities. The competitive landscape means ...

Bkemv is being offered at 10% off Soliris, and Epysqli is offered at 30% below Soliris. Both biosimilars treat several of the ...

Alexion, and AstraZeneca Rare Disease have reported positive topline outcomes from the Phase III KOMET trial, assessing the efficacy and safety of oral Koselugo for treating adults with ...

Based on the terms of the agreement, BridgeBio will receive a $30 million milestone payment upon approval in Japan, as well ...

Alexion, AstraZeneca Rare Disease, and DHL Express have teamed up to initiate Ireland's “first” complete transition to sustainable aviation fuel (SAF) for the international air delivery of ...

BridgeBio Pharma’s Beyonttra to treat transthyretin-mediated amyloid cardiomyopathy receives Japanese approval: Palo Alto, California Monday, March 31, 2025, 17:00 Hrs [IST] Bri ...

In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated The approval was based on a Japanese Phase 3 study and the global ...